Avalo Therapeutics (AVTX) Short term Debt (2014 - 2025)
Avalo Therapeutics posted quarterly Short term Debt of $370000.0 for Q2 2025, up 2.78% on a QoQ basis from $360000.0 in Q1 2025.
Avalo Therapeutics (AVTX) has 8 years of Short term Debt data on file, last reported at $370000.0 in Q2 2025.
- For the quarter ending Q2 2025, Short term Debt changed N/A year-over-year to $370000.0; the trailing twelve-month figure through Jun 2025 stood at $370000.0 (changed N/A YoY), and the FY2024 full-year result was $360000.0, changed N/A from the prior year.
- Short term Debt for Q2 2025 stood at $370000.0, up from $360000.0 in the prior quarter.
- Across five years, Short term Debt topped out at $370000.0 in Q2 2025 and bottomed at $360000.0 in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 370,000.00 |
| Mar 31, 2025 | 360,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2019 | 1.05 Mn |
| Jun 30, 2019 | 1.53 Mn |
| Mar 31, 2019 | 2.21 Mn |
| Dec 31, 2018 | 859,670.00 |
| Sep 30, 2018 | 1.96 Mn |
| Jun 30, 2018 | 1.05 Mn |
| Mar 31, 2018 | 829,263.00 |
| Jun 30, 2017 | 607,598.00 |
| Mar 31, 2017 | 1.49 Mn |
| Dec 31, 2016 | 2.35 Mn |
| Sep 30, 2016 | 3.19 Mn |
| Jun 30, 2016 | 3.39 Mn |
| Mar 31, 2016 | 3.30 Mn |
| Dec 31, 2015 | 3.21 Mn |
| Sep 30, 2015 | 3.13 Mn |
| Dec 31, 2014 | 1.91 Mn |